Objective: Cannabis is the most commonly consumed illicit drug among pregnant women. Intrauterine exposure to cannabis may result in risks for the developing fetus. The importance of intrauterine growth on subsequent psychological and behavioral child development has been demonstrated. This study examined the relation between maternal cannabis use and fetal growth until birth in a population-based sample. Method: Approximately 7,452 mothers enrolled during pregnancy and provided information on substance use and fetal growth. Fetal growth was determined using ultrasound measures in early, mid-, and late pregnancy. Additionally, birth weight was assessed. Results: Maternal cannabis use during pregnancy was associated with growth restriction in mid-and late pregnancy and with lower birth weight. This growth reduction was most pronounced for fetuses exposed to continued maternal cannabis use during pregnancy. Fetal weight in cannabis-exposed fetuses showed a growth reduction of j14.44 g/week (95% confidence interval j22.94 to j5.94, p = .001) and head circumference (j0.21 mm/week, 95% confidence interval j0.42 to 0.02, p = .07), compared with nonexposed fetuses. Maternal cannabis use during pregnancy resulted in more pronounced growth restriction than maternal tobacco use. Paternal cannabis use was not associated with fetal growth restriction. Conclusions: Maternal cannabis use, even for a short period, may be associated with several adverse fetal growth trajectories.
because research has demonstrated the importance of indicators of intrauterine growth, such as birth weight, body weight, and head size, regarding subsequent child development.
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Maternal cannabis use could affect fetal growth through several underlying mechanisms. First, tobacco use leads to attenuated intrauterine growth because of fetal oxygen deprivation caused by a combination of increased carboxyhemoglobin levels in the blood and a decreased maternal blood supply to the placenta. 14, 15 Second, the cannabinoid receptor system is present and functional in early pregnancy 16 and cannabis metabolites could directly affect the brain and body by altering cannabinoid and related neurotransmitter or neuroendocrine systems. Recent studies have shown that endocannabinoids bind to cannabinoid receptors in pancreatic "-cells and regulate the intracellular calcium concentration, consequently decreasing glucose-dependent insulin secretion. 17Y20 The major fetal growth factors are insulinlike growth factors 1 and 2, which are regulated by insulin itself. 21 Therefore, it may be that fetuses prenatally exposed to cannabis have lower insulin levels compared with the controls, which could lead to impaired growth. Finally, epiphenomena of maternal cannabis use, including maternal stress, co-use of other substances, or poor nutritional status during pregnancy, may each have contributed to differences in fetal growth between cannabis users, tobacco users, and nonusers. 22 We are aware of two longitudinal studies that have previously addressed the influence of maternal cannabis use during pregnancy on behavioral outcomes in human offspring. 23, 24 These studies found associations between intrauterine cannabis exposure and offspring neurodevelopmental and behavioral problems, such as tremors and startles in newborns, 25 decreased mental scores measured with the Bayley Scales of Infant Development in infants at 9 months of age, 26 lower intelligence scores measured with the Stanford-Binet Intelligence Scale at 3 years of age, 27 and more teacher-rated delinquent behaviors at 6 and 10 years of age. 28, 29 Part of these findings may originate in adverse fetal growth trajectories. To date, results of human studies on fetal consequences of maternal cannabis use in pregnancy remain inconclusive. 30Y37 Several reasons could account for the inconsistencies across studies. First, birth weight was a main outcome of many studies, but birth weight is just a proxy for fetal growth that can be reached through different individual growth patterns.
Second, most studies lacked sufficient power and inferred their conclusion from observations from small, nonrepresentative samples. Finally, differences in potency of cannabis used in these studies may have accounted for inconsistencies.
The current investigation takes these methodological limitations into account and is the first to focus on the relation between potent maternal and paternal cannabis use during pregnancy and fetal growth using ultrasound measurements in early, mid-, and late pregnancy in a large population-based cohort. Because available data suggest that birth weight is negatively associated with intrauterine cannabis exposure, we hypothesized to find a negative association between fetal growth trajectories and cannabis exposure.
METHOD
This study was embedded in the Generation R Study, a multiethnic population-based prospective cohort study from fetal life onwards, designed to identify early environmental and genetic determinants of growth, development, and health. 38, 39 The cohort included 9,778 mothers and their children living in Rotterdam, the Netherlands. Enrollment was aimed at early pregnancy (gestational age <18 weeks) but was possible until birth of the child. Measurements were planned in early (<18 weeks), mid-(18Y25 weeks), and late pregnancy (Q25 weeks). Seventy-one percent of the partners were enrolled during pregnancy (n = 6,347). The Medical Ethics Committee of Erasmus MC in Rotterdam, the Netherlands, has approved the study in accordance with the Declaration of Helsinki of the World Medical Association. Written informed consent was obtained from all the participants.
All pregnant women residing in the study area at their delivery date between April 2002 and January 2006 were invited to participate. In total, 8,880 mothers were enrolled during pregnancy and were eligible for the present analyses. 38 The mothers without information about substance use (14.3%, n = 1,270) and women who used other drugs but not cannabis (n = 79) were excluded. The mothers with twin pregnancies (n = 78) were excluded. One mother did not have any ultrasound examination and was also excluded. Of the remaining mothers (n = 7,452) who were included in the analyses, 71.4% (n = 5,324) had three ultrasound assessments, 23.7% (n = 1,763) had two, and 4.9% (n = 365) had only one ultrasound assessment. In this study, 74.0% of the fathers participated, and 81.1% of them (n = 4,475) provided substance use information.
The women without information on substance use (n = 1,270) were excluded. Nonresponse analyses showed that these women were somewhat younger (29.1 T 5.5 y) than the women with information on substance use (29.7 T 5.3 years) ( p < .01), less educated (15.7% primary educated versus 11.3%; p < .01), and less likely to be married (21.3% married versus 48.1%; p < .05). No significant differences in national origin were present.
Measures
Exposure Information. Timing and frequency of substance use (daily, weekly, and monthly) were measured using a self-report questionnaire at enrollment. A distinction was made between the use of cannabis (marijuana and hashish) and other illicit drugs (cocaine, amphetamines, and heroin). At enrollment, we explicitly asked with two questions whether pregnant women used substances (tobacco, alcohol, and illicit substances) before pregnancy and whether they had used any of the substances during the previous 3 months. The period of the previous 3 months was chosen in this question because enrollment was aimed at early pregnancy. In the second question, the answer options were ''No,'' ''Yes, until I knew I was pregnant,'' and ''Yes, I still use substances.'' The mothers were asked about their own substance use and about substance use of the biological father. In addition, participating partners reported on their own substance use. Identical questions were answered for tobacco use. Maternal cannabis was codified into a variable with four nonoverlapping categories: continued cannabis use, cannabis use in early pregnancy, cannabis use only before pregnancy, and nonuse (no cannabis or tobacco use during pregnancy). Similar variables were created for tobacco and for alcohol use (Table 1) .
Fetal Growth Information. Fetal ultrasound assessments were performed at research centers and were performed in early, mid-, and late pregnancy. Femur length, abdominal and head circumference, and transcerebellar diameter were measured using standardized techniques. 40 Fetal weight was estimated using femur length and head and abdominal circumference using the formula of Hadlock.
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The intraobserver and interobserver reliabilities of fetal biometry in early pregnancy within Generation R were good; all intraclass correlation coefficients were greater than 0.98. 42 The ultrasound measurements were performed using an Aloka Model SSD-1700 (Tokyo, Japan) or an ATL-Philips Model HDI 5000 (Seattle, WA) equipped with a 5.0 MHz, high-frequency curved array transducer. Confounding Variable Information. Maternal age, educational level, national origin, alcohol use, parity (0 or Q1), and gravidity (1 or Q2) were assessed with questionnaires and considered as possible confounders. Maternal national origin was defined according to the classification of Statistics Netherlands 43 : Dutch, Cape Verdean, Moroccan, Turkish, Surinamese, Antillean, and other national origin. Educational level was categorized into primary, secondary, and higher education. 44 Timing and frequency of alcohol use were measured with similar questions as for tobacco and substance use during pregnancy. Information on maternal anthropometrics was collected in the research centers. The Brief Symptom Inventory, a validated 53-item self-report symptom inventory, was used to ascertain psychological state. 45 The SD score of the Global Severity Index scale of the Brief Symptom Inventory was used to determine general psychopathology. Fetal sex was obtained from midwives and hospital registries. Note: Values are means (SD) for continuous variables and percentages for categorical variables. Analysis of variance with post hoc comparison for continuous variables and # 2 tests for categorical variables versus nonusers was used. a Statistical analysis on tobacco use was not performed because the groups were selected on the basis of this variable. *p < .05; **p < .01.
Statistical Approach
We used multiple linear regression models to examine the associations between maternal cannabis and tobacco use with fetal parameters in mid-and late pregnancy and at birth. These models also were used to examine a potential dose-response association between cannabis use and birth weight. First, the effects of cannabis use during pregnancy were investigated using nonusers as a reference group. Second, the same analyses were performed with tobacco users as a reference group.
We analyzed the association between maternal cannabis and tobacco use and repeatedly measured fetal growth parameters using longitudinal multilevel analysis to account for the dependency between measurements in the same subject. 46 First, we constructed the best fitting model with the outcome as a function of gestational age using fractional polynomials. 47 Because fetal size and transcerebellar diameter were not measured reliably in early pregnancy, the analyses were conducted with mid-and late pregnancy measures and birth measures for estimated fetal weight and with mid-and late pregnancy measures for transcerebellar diameter. The measurements from early until late pregnancy were used for head circumference. Then, maternal cannabis and tobacco use were entered into the model as the main independent variable. The final curve was fitted with random effects for both intercept and gestational age because it takes within-and between-individual variation into account. All other covariates were fitted as fixed effects because there was no a priori reason to assume that these covariates have varying effects for each individual. The interaction term of maternal cannabis/tobacco use with gestational age was included in the model to compare the slope of the curves of different categories of maternal cannabis/ tobacco use with the reference group (nonuse). Additional analyses were performed with the tobacco users as the reference group to determine whether effects of cannabis during pregnancy significantly differed from the effects of tobacco. Moreover, we used an alternative approach in which maternal cannabis and tobacco use were put into the model as separate variables. By doing so, we could assess the effect of cannabis adjusted for the effect of tobacco. To account for residual confounding, supplementary analyses were performed to assess the independent contribution of paternal cannabis on fetal growth.
All models were adjusted for gestational age, maternal age, body mass index, height, education, national origin, maternal alcohol use, parity, gravidity, fetal sex, and maternal psychopathology. 48 We conducted all data analyses using SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL) and SAS v.8.2 (SAS Institute Inc., Cary, NC), including the Proc Mixed module for longitudinal multilevel analyses. Table 1 shows the characteristics of pregnant women per cannabis use category (n = 7,452). In this study sample, 245 women (3.3%) used cannabis only before pregnancy, and 214 women (2.9%) used cannabis before and during early pregnancy. Of these 214 women, 173 (81%) quit using cannabis in early pregnancy, whereas 41 (19%) continued using cannabis throughout pregnancy. In total, 1,453 mothers (19.5%) smoked tobacco during pregnancy (but used no cannabis). All other women (n = 5,540) did not use cannabis or tobacco during pregnancy (nonusers). Of the women using cannabis during pregnancy, 85% also smoked tobacco during pregnancy. The number of daily smoked cigarettes did not significantly differ between women who smoked tobacco and used cannabis versus women smoking tobacco only; 50% smoked more than five cigarettes per day (# 2 10 = 15.35, p = .120). Table 1 shows that cannabis users had lower education levels and were more likely to drink alcohol than nonusers. No difference in gestational duration among the groups was present (Table 1) . Tables 2 and 3 represent the associations between maternal cannabis use and different fetal growth parameters. Using cannabis before pregnancy does not affect fetal growth in mid-and late pregnancy or at birth (Table 2) . However, when mothers used cannabis in early pregnancy, fetuses showed reduced growth. It Note: Models were constructed using multiple linear regressions. All values were adjusted for maternal age, body mass index, height, educational level, national origin, maternal alcohol use, gestational age, parity, gravidity, fetal sex, and maternal psychopathology. CI = confidence interval.
RESULTS
a $ represents the increase or decrease of fetal size characteristics in millimeters in the cannabis subgroups using the nonusers as reference.
affected fetal weight from late pregnancy onward and resulted in a decrease of 156 g in birth weight (95% confidence interval [CI] j224 to j89). It also affected growth of head circumference from mid-pregnancy onward (Table 3) . Continued cannabis use during pregnancy showed the largest growth reduction, which was already present in mid-pregnancy (j13.58 g; 95% CI j27.73 to 0.12, p = .052) and resulted in a growth reduction of 277 g at birth (95% CI j409 to j145, p < .001). Fetal weight was also negatively affected by tobacco use from late pregnancy onward (j23.21; 95% CI j34.41 to j12.00, p < .001) and resulted in approximately 85 g less birth weight (j87.41; 95% CI j113.14 to j61.67, p < .001) as compared with nonexposed fetuses. Similarly, maternal tobacco use in pregnancy attenuated growth of head circumference in mid-(j0.41; 95% CI j0.80 to j0.02, p < .038) and late pregnancy (j1.05; 95% CI j1.60 to j0.50, p < .001).
No statistically significant associations were found between maternal cannabis and tobacco use and transcerebellar diameter (data not shown).
We then examined the effects of intrauterine cannabis exposure using the tobacco smokers as reference. At birth, neonates exposed to cannabis use in early pregnancy were 95 g lighter (j95.40; 95% CI j168.27 to j22.54, p = .010), and continued cannabis-exposed neonates were 172 g lighter (j171.68; 95% CI j308.29 to j35.07, p = .014) as compared with neonates exposed only to tobacco. In late pregnancy, fetuses exposed to cannabis in early pregnancy weighed 40 g less (j40.56; 95% CI j71.53 to j9.60, p = .010), and fetuses exposed to persistent cannabis use weighed 67 g less (j67.12; 95% CI j124.32 to j9.92, p = .021) than fetuses exposed only to tobacco. In midpregnancy, the effects of cannabis exposure on the growth parameters were not significantly different from tobacco effects. Table 2 demonstrates that any intrauterine cannabis exposure cannabis was associated with reduced birth weight. Therefore, all cannabis users were pooled to examine potential dose-response associations. Occasional cannabis use (monthly, n = 36) was not significantly associated with a lower birth weight as compared with nonusers (j123.0; 95% CI j263.4 to 17.4, p = .086) and as compared with tobacco users (j83.2; 95% CI j230.3 to 63.9, p = .268). Moderate cannabis use (weekly = 72) was associated with lower birth weight (j149.7; 95% CI j249.7 to j49.7, p = .003) compared with nonusers but not when compared with tobacco users (j85.8; 95% CI j191.3 to 19.7, p = .111). Finally, heavy cannabis use (daily = 69) was associated with the lowest birth weight (j225.7; 95% CI j330.7 to j120.8, p < .001) also when compared with tobacco users (j149.4; 95% CI j260.0 to j38.8, p = 0.008). Table 4 shows the associations between maternal cannabis and tobacco use and prospectively measured growth parameters. Maternal cannabis use was negatively related to head growth and fetal weight. Using cannabis in early pregnancy or throughout pregnancy resulted in reduced fetal growth; fetuses exposed to cannabis in early pregnancy or to continued use grew 11.18 g/week and 14.44 grams/week, respectively, less than fetuses of nonusers (Table 4) . Tobacco-exposed fetuses grew 4.07 g/week (95% CI j5.60 to j2.54, p < .001) less than nonexposed fetuses. This stronger effect of intrauterine cannabis exposure on growth was also found for head circumference. No statistically significant associations were found between maternal cannabis and tobacco use and transcerebellar diameter (data not shown). Note: Models were constructed using multiple linear regressions. All values were adjusted for maternal age, body mass index, height, educational level, national origin, maternal alcohol use, gestational age, parity, gravidity, fetal sex, and maternal psychopathology.
CANNABIS EXPOSURE AFFECTS FETAL GROWTH
Furthermore, we examined the effects of cannabis use compared with the tobacco users as reference. These analyses showed that fetuses exposed to cannabis in early pregnancy grew 7.08 g/week less (95% CI j11.40 to j2.77, p = .001) and continued cannabis-exposed fetuses grew 10.29 g/week less (95% CI j19.01 to j1.57, p = .021) than tobacco-exposed fetuses. No significant differences for growth of head circumference between cannabis-and tobacco-exposed fetuses.
The alternative approach, using cannabis and tobacco as two separate but overlapping variables, showed an association of intrauterine cannabis exposure corrected for smoking and fetal growth reduction. According to this approach, fetuses exposed to cannabis in early pregnancy grew 7.45 g/week less (95% CI j11.65 to j3.25, p < .001) and continued cannabis-exposed fetuses grew 8.90 (95% CI j17.50 to j0.30, p = .043) less as compared with nonexposed fetuses. For the growth of head circumference, no statistically significant association for cannabis exposure corrected for tobacco use was found (continued exposure j0.10 mm/week with 95% CI j0.33 to 0.12, p = .363; early pregnancy exposure j0.06 mm/week with 95% CI j0.17 to j0.05, p = .281). No interaction effects were found of cannabis and tobacco exposure on fetal growth characteristics. Fig. 1 Estimated growth curve and difference in fetal weight because of maternal cannabis use in pregnancy compared with fetuses of mothers who did not use cannabis or tobacco. Estimates of differences were obtained from fitting the fractional polynomial model, adjusted for maternal age, body mass index, height, educational level, national origin, first trimester alcohol use, parity, gravidity, fetal sex, and maternal psychopathology. Note: Longitudinal multilevel models were constructed using fractional polynomials for gestational age. All values were adjusted for maternal age, body mass index, height, educational level, national origin, maternal alcohol use, parity, gravidity, fetal sex, and maternal psychopathology. The slope represents the decrease of fetal size characteristics in grams (fetal weight) and millimeters (head circumference) per week in the cannabis subgroups using the nonusers as reference. GA = gestational age.
Additional analyses on paternal cannabis use and estimated fetal weight showed that, when fathers use cannabis during pregnancy (without maternal cannabis use), fetal growth was not affected. The intercept of growth curve was not different between paternal users (n = 115) and nonusers (n = 2,527) (40.68; 95% CI j56.71 to 138.06, p = 0.41), and the growth rate did not differ either (j1.40 g/week; 95% CI j5.71 to 2.92, p = .53). Similar results were found when mothers reported on the cannabis use of the biological father of their child. The growth rate was not different (j3.08 g/week; 95% CI j6.49 to 0.34, p = .077) between fetuses of fathers who used cannabis (n = 192) and of fathers who did not use cannabis (n = 4,098). However, the intercept of the curve was different (81.19 g/week; 95% CI 3.90Y158.47, p = .040). Figure 1 depicts the differences between the growth curves of estimated fetal weight (with nonusers as reference group) and maternal cannabis use obtained from fitting the fractional polynomial model. This figure shows that using cannabis before pregnancy did not result in a significantly different fetal weight. Furthermore, fetuses exposed to cannabis in early pregnancy had a significantly lower growth rate, compared with the reference group; continued cannabis use was associated with the most pronounced fetal growth reduction.
DISCUSSION
This population-based study shows that exposure to potent cannabis in utero may be related to reduced fetal growth and fetal head size, known risk factors for neurodevelopmental and behavioral problems. Importantly, we found that cannabis use during pregnancy, often combined with tobacco, has an additive effect in late pregnancy and at birth over and above tobacco use. In contrast, in mid-pregnancy, fetal growth deficits seem to be due to tobacco use only. Our findings further suggest that this may be particularly true for those women who continued their cannabis use throughout pregnancy. Even short-term intrauterine cannabis exposure seems to be associated with impaired fetal growth. These associations between maternal cannabis use and fetal growth were independent of lifestyle and socioeconomic factors and are in line with previous studies reporting lower birth weight in cannabis-exposed babies.
33Y35 Moreover, this study suggested a doseresponse association, showing that heavier cannabis use during pregnancy is particularly associated with lower birth weight, independently of other related lifestyle and socioeconomic factors. Interestingly, paternal cannabis use during pregnancy was not associated with fetal growth restriction, which supports the idea that the negative association between maternal cannabis use and fetal growth could be due to intrauterine exposure. 49 Additionally, this idea is supported by the fundamental role of the cannabinoid system in prenatal development. 7 Finally, no effects of cannabis or tobacco use in pregnancy were found on cerebellar size, which was previously shown to apply to tobacco-exposed fetuses in the same study population. 50, 51 To our knowledge, this is the first prenatally ascertained cohort examining the associations of maternal cannabis use in pregnancy with fetal growth characteristics. Strengths of this investigation include the large population-based prospective cohort we used to examine these associations, the use of ultrasound measurements in combination with information collected at birth that enabled us to determine growth trajectories throughout gestation until birth, and the possibility to control for important confounding factors, including lifestyle factors, socioeconomic factors, and known determinants of fetal growth. Moreover, we were able to compare pregnant cannabis users, who often use cannabis in combination with tobacco, with a group of pregnant women who used only tobacco. Because cannabis and tobacco use often co-occur, this is an important addition to the existing literature. In addition, we were able to compare the strength of the associations between maternal and paternal cannabis use and fetal growth.
Our findings should be viewed with several limitations in mind and therefore be cautiously interpreted. First, we used self-reported data on substance use. Both potential misclassification and selection bias may have led to an underestimation of the prevalence of cannabis use and an underestimation of the effects of cannabis exposure on fetal growth and brain size parameters. Second, the effects of maternal cannabis use on fetal characteristics may have been underestimated because the early pregnancy measurements were used for pregnancy dating, assuming that the variation in growth before the first measurement is zero. Third, because, in Western Europe, cannabis use is often combined with tobacco, we compared our cannabis users with tobaccoonly users or controlled for tobacco use. Our findings thus provided information on the effects of cannabis over and above that of tobacco. Information on the effects of cannabis use alone (without tobacco) could not be retrieved from our nonclinical population-based sample. Thus, the effects of cannabis in samples of pregnant women need to be replicated and expanded in other population-based cohorts. Finally, we were not able to determine which teratogenic compounds of cannabis in combination with tobacco bring about the alteration in bodily proportions.
Of interest is our finding that cerebellar size was not affected by maternal cannabis use. This is consistent with the idea that the cerebellum, which is evolutionarily conserved, may be spared when intrauterine growth is impaired. 52 Although intrauterine cannabis exposure did not affect cerebellar size, it may be that cannabis acted on the cerebellum on a molecular level. Therefore, adaptation of the cannabinoid system and related neurotransmitter systems due to stimulation of the cannabinoid receptors at critical stages cannot be excluded. Such changes in the ontogeny of neurotransmitter systems might lead to substantial and long-lasting effects in different behavioral patterns. 53, 54 However, more research is needed to elucidate the underlying mechanisms associated with the potential harmful long-term effects of intrauterine cannabis exposure.
Our findings suggest the importance to educate future mothers about the consequences of prenatal maternal cannabis use. Our findings may imply that different messages could be transmitted to tobacco and cannabis users. Our findings likely reflect that the effects of cannabis exposure, even restricted to early pregnancy, may not be reversible, although quitting tobacco use in early pregnancy is known to be beneficial. Thus, to prevent the potential harmful effects of intrauterine cannabis exposure, women should quit using cannabis before conception.
